ReviewiMetaOmics2026
Microbiome-urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation.
Review in iMetaOmics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BCa) ranks among the most frequently diagnosed malignancies worldwide. The advent of high-throughput sequencing technologies has revealed distinct urinary microbial signatures that differentiate healthy individuals from BCa patients. While growing evidence implicates microbiota dysbiosis in the pathogenesis, progression, and therapeutic response of BCa, establishing a direct causal relationship remains challenging due to methodological heterogeneity across studies. This review summarizes the current knowledge of the human urinary microbiome (urobiome) in both health and disease states. It critically examines the evidence for microbiome involvement in BCa and discusses potential mechanisms, such as chronic inflammation, immune modulation, and genotoxin production, through which the microbiota may influence carcinogenesis. Furthermore, we explore the translational potential of urinary microbiota profiling as a biomarker for risk stratification and for predicting responses to intravesical therapies and immunotherapy in BCa patients. Unraveling the complexities of host-microbe interactions in BCa is essential for developing novel strategies for its prevention and personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.